Findings Support Change to Breast Cancer Screening Guidelines for HL Survivors
Findings support annual breast cancer screening mammography at ages 30-74 for female survivors of Hodgkin lymphoma who received chest radiation.
Diagnosis & Disease Information
Treatment May Increase Risk of Colorectal Cancer in Hodgkin Lymphoma Survivors
Hodgkin lymphoma patients treated with subdiaphragmatic radiation and/or procarbazine have an increased risk of developing colorectal cancer, a study suggests.
Consolidation Regimen Deemed “Highly Active” in Relapsed/Refractory Hodgkin Lymphoma
Consolidation with up to 8 cycles of brentuximab vedotin plus nivolumab appears active in high-risk, relapsed/refractory Hodgkin lymphoma.
Brentuximab Vedotin + Chemo Ups Event-Free Survival in Peds Hodgkin Lymphoma
Event-free survival rate higher in pediatric patients, but no difference seen in the percentage of patients receiving involved-site radiation therapy.
Risk Prediction Models Identify Hodgkin Lymphoma Survivors at Risk for CVD
Researchers sought to determine risk predictors for coronary heart disease and heart failure in Hodgkin lymphoma survivors who were aged 18 to 50 at diagnosis.
First-Line Brentuximab Vedotin With AVD Improves Survival in Stage III or IV Hodgkin Lymphoma
Researchers sought to determine whether adding brentuximab vedotin to AVD would improve survival in patients with stage III or IV Hodgkin lymphoma.
High Risk of Secondary Lung Cancer Seen in Hodgkin Lymphoma Survivors
Survivors of Hodgkin lymphoma may have a higher risk of developing lung cancer than former smokers, a study suggests.
Targeted Radiotherapy Remains Important in Pediatric Hodgkin Lymphoma With Slow Early Response to Chemotherapy
Researchers sought to assess the importance of radiotherapy in pediatric patients with early‐stage low-risk classical Hodgkin lymphoma.
Response-Adapted Nivolumab Salvage Therapy Safe and Effective in Classical Hodgkin Lymphoma
Researchers sought to determine whether response-adapted sequential salvage therapy would be effective in patients with relapsed/refractory classical Hodgkin lymphoma.
Survival Advantage Seen for A+ADV in Advanced Hodgkin Lymphoma
Progression-free survival longer for brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine versus ABVD.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...